CAR-T In Vitro Efficacy Services with OncoSolid™ Nasopharyngeal Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Nasopharyngeal Carcinoma Organoid Models

Nasopharyngeal carcinoma is a dominant subset of head and neck cancer and presents a high incidence rate in populations. Radiation treatment is adopted for primary nasopharyngeal carcinoma deletion but is not effective for recurrent cases. Typical 2D cell models have limitations in reflecting the complex tumor tissue and hinder the study of tumor pathogenesis and recurrence and the development of novel effective anti-tumor reagents. Cancer organoid models are mini-tumor tissue that is cultured in vitro and recapitulates key characteristics and functions of organs. Due to increased clinical relevance, organoids are widely used for basic research and personal medicine.

Nasopharyngeal Carcinoma Organoid-models Mediated CAR-T Efficacy Test at Creative Biolabs

With cutting-in-edge organoid culture technologies, Creative Biolabs offers a living biobank of cancer organoid models for CAR-T anti-tumor efficacy tests in vitro. Our one-stop service includes organoid generation, organoid characterization, and organoid application in immunotherapy development.

Workflow

Fig.1 Working steps of CAR-T in vitro anti-tumor efficacy test with nasopharyngeal cancer organoid models. (Wang, et al., 2020)

Key Features

High Success Rate

Generate organoids with an improved establish rate.

Mimic in Vivo Tumor Tissue

Provide a cohort of cancer organoids derived from different tissue sites of tumor and resemble tumor heterogenicity.

Experienced expert team

Multi-field expert-led experienced technicians and pathologists for individual subjects.

Organoid Characterization

Verified From Various Aspects

Morphology
Histopathology
Genomics

Techniques

H&E Staining
IHC (Immunohistochemistry)
ISH (In Situ Hybridization)
IF (Immunofluorescence)
NSG (Next-generation-sequencing)

Biomarkers Identification

Tumor marker: EBERs, LMP1
Differentiation marker:
ISH (In Situ Hybridization)
Stem cell marker: BMI-1, CD44, and CD133

Optimal Culture System

We have established an improved protocol to generate cancer organoids.

The highly efficient enzymatic treatment process for tumor samples
Optimized components and concentration of cytokines and growth factors for the organoid generation
Decreased cost and simplified manipulation procedures

Pre-experiment

Co-culture method development
Unique culture medium to support both cell growth
Cell-labeling

Co-culture Assay

Cell viability
Cell migration
Cell invasion
Cell cytotoxicity
Antigen-specific killing
Antigen expression
Effector production

Technologie

ELISA
Flow cytometry analysis
Immunofluorescent
Microscopy imaging
IHC
RT-PCR

Nasopharyngeal Cancer-related CAR-T Products for Cytotoxicity Test

Organoids are versatile models to predict CAR-T in vivo anti-tumor efficacy. As a lead provider in immunotherapy development, we provide cancer-targeted, high-quality CAR-T products that can be directly applied to test cytotoxicity against cancer organoid models.

Target Antigen	Target Description	CAR-T Product
LMP1	EB virus infection is the cause of Nasopharyngeal cancer. LMP1 is a membrane protein produced by EBV and is involved in tumor pathogenesis, survival, metastasis, and tumor microenvironment shaping.	Anti-LMP1 CAR-T

Creative Biolabs offers cancer organoids with high physiological relevance to facilitate CAR-T therapy development and in vivo efficacy analysis. Our service repertoire contains cancer epitope analysis, antigen-targeted immunotherapies development, in vitro and in vivo efficacy tests, etc. Please contact us for an optimized protocol for your cancer organoid study.

Reference

Wang, X. W.; et al. Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma. Annals of translational medicine. 2020, 10(9): 526.